ArticleBMJ open2022

Efficacy, safety and cost-effectiveness of methotrexate, adalimumab or their combination in non-infectious non-anterior uveitis: a protocol for a multicentre, randomised, parallel three arms, active-controlled, phase III open label with blinded outcome assessment study.

Ana Belen Rivas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.